June 25 (Reuters) - Teva Pharmaceutical Industries

has entered into a deal with the Israel Tax Authority

to resolve all pending litigation related to taxes payable for

the years from 2008 to 2020, the drugmaker said on Tuesday.

Under the agreement, Teva will pay $750 million in

installments between 2024 and 2029.

In future, if Teva pays dividends on, or repurchases, its

equity interests, the company will pay an additional 5%-7% of

the amount of such dividends or repurchases in corporate taxes,

up to a maximum amount of about $500 million.

Teva said the deal has no impact on its 2024 financial

outlook.